Subtype
Malignant Soft Tissue Neoplasm of Uncertain Differentiation
CI-CAN-00001179Explore in graph →
66 active trials2 approved drugs25 evidence items
- NCIt
- C6588
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001179Explore in graph →
Clinical trials
186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (29)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04616560 | Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor | recruiting | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07174427 | Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma | recruiting | Phase 3 | 5 | Takara Bio Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05333458 | Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial | recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06066138 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07297667 | GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours | recruiting | Phase 1 | 30 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05711615 | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07613723 | A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies | recruiting | Phase 1 | 9 | Zelluna Immunotherapy ASINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05918640 | Lurbinectedin in FET-Fused Tumors(LiFFT) | recruiting | Phase 1 / Phase 2 | 63 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07328425 | Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS(ISG-TULIPS) | recruiting | Phase 2 | 20 | Italian Sarcoma GroupNETWORK | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07261657 | N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy | recruiting | Early Phase 1 | 8 | Seth PollackOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05642455 | SPEARHEAD-3 Pediatric Study | recruiting | Phase 1 / Phase 2 | 20 | USWM CT, LLCINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04999761 | AB122 Platform Study | recruiting | Phase 1 | 917 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06083883 | Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 | recruiting | Phase 1 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05227326 | AOH1996 for the Treatment of Refractory Solid Tumors | recruiting | Phase 1 | 92 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06571734 | XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma | recruiting | Phase 2 | 73 | Northwestern UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05910307 | Synovial Sarcoma Registry / Biospecimen Repository | recruiting | — | 1,000 | Children's Hospital of PhiladelphiaOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT06094101 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)(PerVision) | recruiting | Phase 1 / Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04332874 | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548177 | Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma | recruiting | Phase 2 | 33 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03016819 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)(APROMISS) | recruiting | Phase 3 | 325 | Advenchen Laboratories, LLCINDUSTRY | 5 | Feb 25, 2026 | clinicaltrials |
| NCT07432932 | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients(PANTHR-S) | recruiting | — | 800 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06709495 | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas | recruiting | Phase 1 / Phase 2 | 63 | David S Shulman, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03967834 | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group(MIRAS) | recruiting | N/A | 400 | Institut Claudius RegaudOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT07169344 | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma(PROSARC-1) | recruiting | Phase 2 | 110 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07173972 | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.(PROSARC-2) | recruiting | Phase 2 | 40 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | recruiting | Phase 1 | 25 | Baylor College of MedicineOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04690374 | Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor | recruiting | — | 250 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 | recruiting | Phase 1 | 15 | Immatics US, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06942442 | A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma | recruiting | Phase 2 | 47 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03099681 | An Observational Study on Epithelioid Sarcoma(EPISObs) | recruiting | — | 100 | Italian Sarcoma GroupNETWORK | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07153887 | Vebreltinib for Advanced or Metastatic CCS | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT06836505 | Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. | recruiting | Phase 1 / Phase 2 | 10 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06456359 | Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor(PAMSARC) | recruiting | Phase 2 | 28 | University Hospital HeidelbergOTHER | 1 | Jan 13, 2025 | clinicaltrials |
Data updated 20 hours agoSource updated Sep 29, 2026source: clinicaltrials